Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Clinigen Group PLC | MaxCyte | Cello Health PLC | Oncimmune | Silence Therapeutics PLC

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.

 

This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

 

The event is not suitable for people pursuing commercial opportunities.

Cello Health PLC

RSS Portfolio

1524747689_Cello-Health-plc-logo_540x240px-(002).png


We are a global healthcare-focused advisory group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities.

We currently service 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

We enable clients to differentiate their propositions and drive brand success in ever more complex global markets. We deliver our services through nearly 1,000 highly skilled professionals utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York, Philadelphia, London, Edinburgh, Farnham and Cheltenham.

EPIC: CLL
Market: AIM
52-week High/Low: 140.07p / 95.00p
Market Cap: 128.76M


View full company profile

Clinigen Group PLC

RSS Portfolio

1561036171_clinigen.png


Clinigen (Clinigen Group) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines to improve the quality of people's lives around the world.

We are the global leading experts, trusted by both pharmaceutical and biotech companies and healthcare professionals, in providing access to medicines throughout the lifecycle of a medicine; clinical trials, unlicensed and commercial supply.

Clinigen’s mission is to deliver the right medicine to the right patient at the right time operating in three areas of global medicine supply: clinical trials, unlicensed and licensed medicines.

Operating in a complex regulatory environment, Clinigen is the only company to globally manage access to medicine across all three routes worldwide. We understand the complex challenges facing Pharmaceutical and Biotech companies and are uniquely placed to provide the solutions to help.

Clinigen add insight, expertise and value at every stage of a product’s lifecycle, supporting pharmaceutical companies and healthcare professionals from clinical trials, unlicensed supply and  full commercialisation of medicines. That is why, for over 30 years, Clinigen has been trusted by industry and healthcare providers to enable access to more innovative medicines, in more countries, for more patients than anyone else.

EPIC: CLIN
Market: ISE
52-week High/Low: 1,069.00p / 716.00p
Market Cap: 1,338.04M


View full company profile

MaxCyte

RSS Portfolio

1523368175_Maxcyte.png


We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines.

We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.

This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.

We are developing CARMA, our proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture chimeric antigen receptor (CAR) therapies for a broad range of cancer indications, including solid tumors where existing chimeric antigen receptor T cell (CAR-T) approaches face significant challenges. To read more click here.

 

EPIC: MXCT
Market: AIM
52-week High/Low: 247.50p / 147.00p
Market Cap: 86.51M


View full company profile

Oncimmune

RSS Portfolio

1557218511_Oncimmune.png


Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both immuno-oncology and autoimmune disease. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune’s tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally.

EPIC: ONC
Market: AIM
52-week High/Low: 138.50p / 77.00p
Market Cap: 54.71M


View full company profile

Silence Therapeutics PLC

RSS Portfolio

1508314642_sil.png


Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

EPIC: SLN
Market: AIM
52-week High/Low: 175.00p / 40.00p
Market Cap: 50.51M


View full company profile

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use